Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure

Abstract

Chronic heart failure (CHF) is a critical public health issue with increasing effect on the healthcare budgets of developed countries. Various decision-analytic modelling approaches exist to estimate the cost effectiveness of health technologies for CHF. We sought to systematically identify these models and describe their structures. We performed a systematic literature review in MEDLINE/PreMEDLINE, EMBASE, EconLit and the Cost-Effectiveness Analysis Registry using a combination of search terms for CHF and decision-analytic models. The inclusion criterion required 'use of a mathematical model evaluating both costs and health consequences for CHF management strategies'. Studies that were only economic evaluations alongside a clinical trial or that were purely descriptive studies were excluded. We identified 34 modelling studies investigating different interventions including screening (n = 1), diagnostics (n = 1), pharmaceuticals (n = 15), devices (n = 13), disease management programmes (n = 3) and cardiac transplantation (n = 1) in CHF. The identified models primarily focused on middle-aged to elderly patients with stable but progressed heart failure with systolic left ventricular dysfunction. Modelling approaches varied substantially and included 27 Markov models, three discrete-event simulation models and four mathematical equation sets models; 19 studies reported QALYs. Three models were externally validated. In addition to a detailed description of study characteristics, the model structure and output, the manuscript also contains a synthesis and critical appraisal for each of the modelling approaches. Well designed decision models are available for the evaluation of different CHF health technologies. Most models depend on New York Heart Association (NYHA) classes or number of hospitalizations as proxy for disease severity and progression. As the diagnostics and biomarkers evolve, there is the hope for better intermediate endpoints for modelling disease progression as those that are currently in use all have limitations.

Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model

“…21 NO. 40 Goehler et al, 74 in a review of HF decision-analytical models, found similar numbers of models using NYHA class (n = 9), rehospitalisation (n = 6) or alive/dead health states (n = 10) to track disease progression and survival. They note that the choice of model structure is dependent on, among other factors, data availability.…”

Economic Evaluation of Cardiac Contractility Modulation (CCM) Therapy with the Optimizer IVs in the Management of Heart Failure Patients

“…Also quality of life has been modeled on the assumption of improved performance on the MLWHFQ. Nonetheless, a recent review of economic models in HF has indicated that quite often this is the chosen approach to economic modeling for several new pharmaceuticals and medical devices in HF patients 32 . This is because whilst NYHA class classification involves a subjective assessment of the health status of HF patients, there is abundant evidence in the literature, from studies in different settings and populations, which indicates that patient NYHA class status is a predictor of mortality International Cardiovascular Forum Journal 4 (2015) DOI: 10.17987/icfj.v4i0.173…”

Simulation model for cost estimation of integrated care concepts of heart failure patients

“…Goehler et al identified 34 modelling studies investigating different interventions [21]. Most of them used Markov models (27) and a few used mathematical equation sets (4) or discrete event simulation (3) models.…”